Jia‐Ying Li

Jia‐Ying Li

Auto-generated profile, based on publicly available information

Jia‐Ying Li

Wenzhou Medical University Wenzhou China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Clinical Case Reports
Verified
Journal Article
Open access
XSXia‐Bo Shen
Xia‐Bo Shen
JWJia‐Yi Wu
Jia‐Yi Wu
JLJia‐Ying Li
Jia‐Ying Li
XSXiying Shao
Xiying Shao
XWXiaojia Wang
Xiaojia Wang
Key Clinical Message: In a patient with metastatic breast cancer, an acquired BRCA mutation in the BRCA gene was detected, resulting in benefits from olaparib treatment. This underscores the importance of ongoing genetic phenotype testing after paclitaxel chemotherapy. Triple‐negative breast cancer (TNBC) is associated with a poor prognosis and elevated mortality risk. BRCA mutations are commonly regarded as prevalent mutations in TNBC patients, strongly associated with congenital familial heredity. Dynamic changes in mutation sites, however, are rarely reported. In this case report, we report a 59‐year‐old TNBC patient who developed pulmonary metastases post‐chemoradiotherapy. No BRCA mutations were detected through NGS. After 7.6 months of nab‐paclitaxel treatment, the patient experienced progression of lung metastases, and BRCA mutations were detected through NGS testing. Subsequent administration of olaparib resulted in a reduction in lung metastasis, demonstrating significant therapeutic efficacy. This case underscores the infrequent occurrence of treatment‐induced BRCA mutations and emphasizes the significance of dynamic NGS genetic testing for real‐time assessment of a patient's mutational status.